不同剂量瑞舒伐他汀对冠状动脉粥样硬化斑块及血管内皮细胞功能的影响

目的:探讨不同剂量瑞舒伐他汀对冠状动脉粥样硬化斑块及血管内皮细胞功能的作用.方法:选取冠状动脉粥样硬化病人86例,随机分为观察组和对照组,各43例.对照组采用小剂量瑞舒伐他汀(10 mg)治疗;观察组采用大剂量瑞舒伐他汀(20 mg)治疗,持续治疗3个月.比较2组病人血管体积、管腔体积、斑块体积及肱动脉血流介导的舒张功...

Study on the effects of different doses of rosuvastatin on coronary atherosclerotic plaques and vascular endothelial cell function

ObjectiveTo investigate the effects of different doses of rosuvastatin on coronary atherosclerotic plaques and vascular endothelial cell function.MethodsEighty-six coronary atherosclerotic patients were randomly divided into the observation group and control gorup(43 cases in each gorup). The control group was treated with 10 mg of rosuvastatin, and the observation group was treated with 20 mg of rosuvastatin for 3 months. The volume of blood vessels, volume of lumen, volume of plaque, flow-mediated vasodilation(FMD), nitroglycerin-mediated vasodilation(NMD) and nitric oxide(NO) were compared between two groups, and the adverse reactions in two groups were also recorded.ResultsThere was no statistical significance in the vascular volume, lumen volume and plaque volume between two groups before treatment(P > 0.05). After treatment, the vascular volume, lumen volume and plaque volume in two groups decreased compared with those before treatment(P < 0.05), and which in observation group were less than those in control group(P < 0.05 to P < 0.01). There was no statistical significance in the FMD, NMD and NO between two groups before treatment(P > 0.05). After treatment, the FMD, NMD and NO in two groups increased compared with before treatment, and the FMD, NMD and NO in observation group were significantly higher than those in control group(P < 0.01). No acute cardiovascular events occurred in two groups during treatment. The incidence rate of adverse reactions in observation group and control group were 9.30%(4/43) and 6.98%(3/43), respectively, and the difference of which between two groups was not statistical significance(P > 0.05).ConclusionsCompared with 10 mg rosuvastatin, the 20 mg of rosuvastatin in the treatment of coronary atherosclerotic plaque can improve the plaque and vascular endothelial cell function, with good toleracnce and safety.